Viennese biotech company Marinomed Biotechnologie has licensed the rights of five drugs to a global pharmaceutical firm for the Chinese market.
The drugs include three antiviral nasal sprays against common cold, influenza and colds in children, an antiviral lozenges and a throat spray against viral throat infections,
Marinomed CEO Dr Andreas Grassauer said that China is the third largest pharmaceuticals market globally and offering license to its whole product portfolio for the country is one step ahead towards its rapidly growing sales and distribution network.
The entire product portfolio is based on the MAVIREX technology platform, which allows the development of therapies against more than 200 different respiratory virus strains on the basis of natural substances derived from red algae.
Based on the terms of the agreement, the pharma partner has also received the production rights, besides getting rights for the marketing of Marinomed's current cold remedy portfolio.
The Viennese drug maker is extensively working on the development of new products on the basis of the MAVIREX technology platform, besides expanding its numerous sales channels though the globe.
